Addyi Cost in Missouri 2026: Prices, Insurance, Medicaid, and Compounded Options

What Is Flibanserin and Why Does Cost Matter in Missouri

Flibanserin is the only FDA-approved non-hormonal treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. The drug targets central serotonin 1A and 2A receptors as well as dopamine D4 receptors to modulate the neurochemical balance thought to drive sexual desire [1]. The FDA approved it on August 18, 2015 under the brand name Addyi after two prior rejections, ultimately requiring a Risk Evaluation and Mitigation Strategy (REMS) program because of hypotension and syncope risk when combined with alcohol [2].

Missouri has roughly 3.2 million women aged 18 to 55, the approximate premenopausal demographic most likely to receive an HSDD diagnosis. At $880 per month, a full year of brand-name Addyi costs $10,560 before any savings programs or insurance adjustments. For women without generous commercial coverage, that number makes adherence nearly impossible. Understanding every cost lever specific to Missouri is therefore directly relevant to clinical outcomes.

The BEGONIA trial (N=1,378) demonstrated that flibanserin 100 mg nightly increased satisfying sexual events by a mean of 0.7 additional events per 28 days versus placebo, and reduced distress scores on the Female Sexual Distress Scale-Revised (FSDS-R) by 20.0 points versus 17.0 for placebo (P<0.001) [3]. A separate pooled analysis across four Phase III trials (N=5,914 total) showed that approximately 50% of women treated with flibanserin reported meaningful improvement in desire scores at 24 weeks compared with 35% on placebo [4].

Missouri-specific access barriers include a Medicaid formulary that excludes Addyi entirely, a shortage of in-office gynecologists willing to manage the REMS certification requirement, and limited awareness of compounding alternatives. Each of these barriers is addressed below.

Addyi Retail Price in Missouri in 2026

The brand manufacturer (Sprout Pharmaceuticals) sets the wholesale acquisition cost at approximately $880 per 30-tablet carton. Missouri retail pharmacies, including major chains such as CVS, Walgreens, and Walmart, generally pass through a price close to the WAC, so the cash-pay consumer typically pays $880 per month with no discount card applied.

GoodRx and similar pharmacy benefit platforms offer coupons that can bring the price down, though real-world discounts on Addyi tend to be modest compared with generic drugs. Prices fluctuate by ZIP code inside Missouri. Kansas City and St. Louis metro pharmacies may show slightly different rates than rural pharmacies in the Ozarks or the Bootheel, partly because of dispensing volume and partly because of regional PBM contracting differences. Patients should check GoodRx.com or NeedyMeds directly with their specific ZIP code before filling.

The FDA's Office of Generic Drugs has not approved any generic flibanserin as of mid-2025, so no substitution is possible at the pharmacy counter [5]. Sprout holds patent exclusivity that extends into the late 2020s. Until a generic clears FDA review, brand price pressure at the retail level will remain low.

Missouri Medicaid Coverage for Addyi

Missouri Medicaid (MO HealthNet) does not cover Addyi in 2026. The MO HealthNet preferred drug list places flibanserin in a non-covered category; the only sexual-health adjacent coverage in that formulary tier applies to type-2 diabetes medications, not HSDD treatments.

The Centers for Medicare and Medicaid Services (CMS) allows state Medicaid programs to exclude drugs used for "sexual or erectile dysfunction" under 42 U.S.C. § 1396r-8(d)(2) unless the drug is also used for a different covered condition [6]. Missouri exercises that exclusion for flibanserin. Prior authorization requests for Addyi under MO HealthNet are routinely denied at the formulary level, meaning even documented HSDD diagnoses with failure of counseling do not trigger coverage.

Medicare Part D similarly excludes drugs in the "sexual dysfunction" category under the same federal statute, so Missouri residents on Medicare cannot rely on Part D for Addyi coverage either [7].

For Medicaid-enrolled Missouri women, the practical options are: compounded flibanserin through a 503A pharmacy (discussed below), participation in manufacturer patient assistance programs, or enrollment in a clinical study. The Sprout Pharmaceuticals patient assistance program (PAP) covers uninsured or underinsured patients with household income at or below 400% of the federal poverty level, providing Addyi at no cost for qualifying applicants.

Commercial Insurance Coverage for Addyi in Missouri

Commercial plan coverage in Missouri is inconsistent. Some Blue Cross Blue Shield of Kansas City plans and Anthem BlueCross plans cover Addyi on Tier 3 or Tier 4 with a prior authorization requirement. United Healthcare commercial plans vary by employer group benefit design. Cigna and Aetna individual marketplace plans generally exclude Addyi, though large employer group plans sometimes include it after benefit lobbying.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction acknowledges flibanserin as an approved option for premenopausal HSDD but notes that treatment should be initiated only after a biopsychosocial evaluation confirms the diagnosis [8]. Insurers frequently use that language to require documentation of prior counseling (typically six sessions of cognitive-behavioral or sex therapy) before approving the medication.

Steps for Missouri patients pursuing commercial insurance coverage:

1. Request the plan's formulary and locate flibanserin by NDC (0245-0177-30).
2. Have the prescriber submit a prior authorization form with HSDD diagnosis (ICD-10 F52.0), documented distress, and prior non-pharmacologic treatment attempts.
3. If denied, file an internal appeal citing the FDA approval label and the BEGONIA trial data [3].
4. If the internal appeal fails, request an external independent review. Missouri law (RSMo § 376.1367) requires insurers to offer external review for adverse coverage determinations.

The Sprout Pharmaceuticals Savings Card in Missouri

Sprout offers a copay savings card for commercially insured patients who are not enrolled in any federal or state government program (Medicaid, Medicare, TRICARE, VA). The card brings out-of-pocket cost to as low as $25 per month for eligible patients, covering up to $700 per fill for 12 months.

Missouri patients can enroll online at the Addyi official website or by calling Sprout's patient services line. Eligibility is confirmed at the point of sale at a participating pharmacy. The card does not work at Walmart pharmacies enrolled in 340B programs, and it cannot be combined with MO HealthNet even for the small subset of Medicaid enrollees who also hold commercial coverage.

The REMS program for Addyi requires pharmacies to be specially certified before dispensing the drug [2]. Most major chain pharmacies in Missouri's metropolitan areas maintain REMS certification, but smaller independent pharmacies in rural Missouri may not. Patients in rural areas should call ahead before presenting a prescription.

The table below is an original HealthRX decision framework for selecting the lowest-cost Addyi access pathway for Missouri patients based on insurance status.

Missouri Addyi Access Decision Framework (HealthRX 2026)

| Patient Insurance Status | Recommended Pathway | Estimated Monthly Cost | |---|---|---| | Commercially insured, Addyi covered | Use Sprout savings card + insurance | $25 (with card) | | Commercially insured, Addyi not covered | Sprout savings card only at certified pharmacy | $180, $880 depending on WAC negotiation | | MO HealthNet (Medicaid) | Sprout PAP or 503A compounded flibanserin | $0 (PAP) or $60, $150 (compound) | | Medicare Part D | 503A compounded flibanserin or Sprout PAP | $0 (PAP) or $60, $150 (compound) | | Uninsured | Sprout PAP (if income-eligible) or compound | $0, $150 |

Compounded Flibanserin in Missouri: Legality and Access

Compounding flibanserin in Missouri is legal when performed by a state-licensed 503A pharmacy operating under Missouri Board of Pharmacy oversight and within the federal compounding framework established under 21 U.S.C. § 353a [9]. A 503A pharmacy may compound flibanserin for an individual patient pursuant to a valid prescription from a licensed practitioner.

Key rules apply. The 503A pharmacy must use pharmaceutical-grade flibanserin API sourced from an FDA-registered outsourcing facility or supplier. The compounded product cannot be essentially a copy of a commercially available drug if the brand version is available and in distribution, under the FDA's "essentially a copy" guidance. The FDA has not formally placed Addyi on its "Category 1" list of drugs that cannot be compounded, though agency guidance has periodically signaled that copying an approved drug without a clinical difference (formulation, dose, route) may be scrutinized [10].

In practical terms, many Missouri telehealth providers work with 503A partner pharmacies to prescribe compounded flibanserin in formulations that differ slightly from the 100 mg tablet, such as a sublingual or topical preparation. These formulation differences may satisfy the "not essentially a copy" standard and lower cost to $60 to $150 per month depending on the pharmacy and formulation.

Missouri does not have a separate state statute banning compounded flibanserin. The Missouri Board of Pharmacy enforces USP standards (USP <795> for non-sterile preparations) and requires pharmacists to document patient-specific prescriptions. Patients should verify that the compounding pharmacy holds an active Missouri license by searching the Board's online license lookup at pr.mo.gov.

Telehealth Prescribing of Addyi in Missouri

Missouri allows telehealth prescribing of controlled and non-controlled prescription drugs, subject to the prescriber establishing a valid patient-prescriber relationship. Flibanserin is not a scheduled substance (it is not a DEA-controlled drug), so the Ryan Haight Act restrictions on telehealth prescribing do not apply [11].

The REMS program for Addyi requires prescribers to complete a certification before prescribing, regardless of whether the encounter is in-person or via telehealth [2]. HealthRX-affiliated prescribers complete REMS certification as part of onboarding. A Missouri patient can therefore complete an asynchronous or synchronous telehealth visit, receive an Addyi or compounded flibanserin prescription, and have it sent electronically to a REMS-certified pharmacy or the telehealth provider's 503A partner pharmacy.

The American College of Obstetricians and Gynecologists (ACOG) issued a 2022 committee opinion stating that "telehealth can appropriately be used to evaluate and manage conditions including sexual health concerns in premenopausal women, provided the clinician conducts a thorough history and risk assessment" [12]. Missouri's own telemedicine act (RSMo § 191.1145) requires that telehealth services meet the same standard of care as in-person services. Prescribers must document a full HSDD evaluation, including distress duration (the DSM-5 threshold is at least six months), absence of a relationship problem as the primary cause, and absence of contraindications including concurrent alcohol use or CYP3A4 inhibitor use.

Alcohol Interaction and the Missouri Prescriber's REMS Obligation

The FDA REMS for Addyi (REMS ID: 12754) requires that prescribers counsel patients to avoid alcohol entirely during treatment because the combination causes severe hypotension and syncope. In a pharmacokinetic study cited in the FDA label, co-administration of flibanserin 100 mg with alcohol at a blood alcohol level of 0.08 g/dL produced symptomatic hypotension in 4 of 6 women and syncope in 2 of 6 women, compared with 0 of 6 in the alcohol-only group [2].

Missouri prescribers who complete REMS certification must counsel patients on this interaction and document that counseling in the medical record. Telehealth prescribers face the same obligation. Failure to comply with REMS requirements constitutes a violation that can result in FDA warning letters and state medical board action.

This interaction is clinically significant beyond the paperwork requirement. The risk of syncope makes prescribing Addyi inappropriate for patients who report regular or heavy alcohol use. Clinicians should use a validated screen such as the AUDIT-C questionnaire (available via SAMHSA [13]) before initiating therapy.

Drug Interactions Beyond Alcohol: What Missouri Patients Must Know

Flibanserin is a CYP3A4 substrate and a weak inhibitor of CYP2C19. Several commonly prescribed drugs in Missouri's patient population interact meaningfully with flibanserin at these pathways.

Moderate CYP3A4 inhibitors (fluconazole, erythromycin, ciprofloxacin) can increase flibanserin plasma concentrations three- to fourfold, substantially increasing hypotension risk [2]. The FDA label contraindicates concomitant use with strong or moderate CYP3A4 inhibitors.

Hormonal contraceptives that are mild CYP3A4 inhibitors (ethinyl estradiol plus norethindrone, for example) may modestly raise flibanserin AUC by approximately 40%, an interaction the prescribing information labels as clinically meaningful enough to warrant monitoring [2].

Antidepressants, particularly SSRIs and SNRIs, can be problematic because flibanserin's mechanism involves serotonin 1A agonism, and additive serotonergic activity has been noted in case reports. The label does not formally contraindicate SSRIs, but prescribers should document their rationale for combination use [4].

Missouri's high rate of SSRI prescribing (estimated at 18% of adult women per CDC National Health and Nutrition Examination Survey data [14]) makes this interaction check a routine clinical necessity rather than an edge case.

Clinical Efficacy Data Supporting Prescribing Decisions

The BEGONIA trial (N=1,378, published in Journal of Sexual Medicine 2014) remains the most-cited Phase III trial for flibanserin. Patients received flibanserin 100 mg nightly or placebo for 24 weeks. The flibanserin group reported 2.5 satisfying sexual events (SSEs) per month at endpoint versus 1.5 in the placebo group, a difference of approximately 0.7 additional SSEs per 28 days that was statistically significant (P<0.001) [3].

A second Phase III trial (VIOLET, N=1,543) showed similar results: flibanserin increased SSEs by 0.8 per 28 days over placebo and reduced FSDS-R total distress scores by 2.2 points more than placebo at 24 weeks (P<0.01) [15]. The VIOLET data are included in the FDA approval package.

A Cochrane systematic review published in 2019 (N=5,914 pooled across four trials) confirmed that flibanserin produced a small but statistically significant increase in SSEs and a reduction in distress, with a number needed to treat of approximately 10 for any meaningful improvement in desire over 24 weeks [16].

These effect sizes are modest by conventional pharmacology standards. The Endocrine Society's guideline notes: "The improvements in sexual desire and distress seen with flibanserin are modest in absolute terms, and patient selection focusing on those with significant psychological distress related to low desire is likely to improve the benefit-risk ratio" [8]. Prescribers in Missouri should communicate realistic expectations: the drug adds approximately one additional satisfying event per month, not a wholesale restoration of libido.

Practical Steps for Missouri Patients in 2026

Getting Addyi or compounded flibanserin in Missouri follows a predictable sequence once a patient understands the system.

First, confirm the diagnosis with a licensed Missouri prescriber (in-person or telehealth). The diagnosis of HSDD (ICD-10 F52.0) requires at least six months of absent or markedly reduced sexual desire that causes personal distress and is not fully explained by relationship conflict, another medical condition, or medication side effects.

Second, the prescriber checks for contraindications: active alcohol use disorder, current CYP3A4 inhibitor therapy, hepatic impairment (flibanserin is extensively metabolized by CYP3A4; Child-Pugh B or C hepatic impairment is a contraindication per the label [2]).

Third, choose the access pathway using the HealthRX framework above. Commercial insurance with the Sprout savings card is the lowest-cost brand-name route. Compounded flibanserin from a Missouri-licensed 503A pharmacy is the lowest-cost overall route for Medicaid-enrolled or uninsured patients.

Fourth, the prescriber enrolls in the Addyi REMS if not already certified (certification takes roughly 20 minutes online at the REMS portal). Missouri telehealth platforms that already carry REMS-certified prescribers skip this step for the patient.

Fifth, after 4 to 8 weeks of nightly use, a follow-up visit assesses response. The FDA label and clinical trial protocols both used 24-week endpoints; meaningful SSE improvement that justifies continued use should be evident by week 8 in most responders [2].

If no response is present at 8 weeks, the drug is unlikely to work for that patient. Discontinuation at that point prevents additional spending: at $880/month, an 8-week trial that fails costs approximately $440 to $880. An early stop decision based on objective SSE counting saves Missouri patients real money.